Mitsubishi Tanabe Pharma Corporation

Hidetaka Miyoshi

Akira Kubo

Tetsu Nakane

Akihito Ogasawara

Tatsuo Nakajima

Ritsuo Imashiro

Hajime Hiramatsu

Hiroaki Sakurai

Takanori Murakami

The present invention relates to a compound of the formula [I]: wherein Gis an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula: wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, Ris hydrogen atom, an alkyl which may be substituted, a cycloalkyl which may be substituted, a phenyl which may be substituted, etc., Z, Z, Zand Zmay be the same or different, and each is CH or N, provided that 3 or more of Z, Z, Zand Zshould not be N at the same time, Gis hydrogen atom, &#x2014;NRR, &#x2014;OR, etc., where Rto Reach is independently hydrogen atom, an alkyl which may be substituted, an alkenyl, an alkynyl, etc., or a pharmaceutically acceptable salt thereof.

4-imidazolin-2-one compounds

The present invention is to provide a novel heterocyclic compound of the formula [I]: 

Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity

The present invention relates to a compound of the formula [I]:  

Growing community of inventors

Osaka, Japan

Hidetaka Miyoshi